Valproic Acid induces CYP3A4 and MDR1 genes expression by activation of Constitutive Androstane Receptor and Pregnane X Receptor pathways

Lukas Cerveny, Lucie Svecova, Eva Anzenbacherova, Radim Vrzal, Frantisek Staud, Zdenek Dvorak, Jitka Ulrichova, Pavel Anzenbacher, and Petr Pavek*

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove (L.C., L.S., F.S., P.P.), Institute of Medical Chemistry and Biochemistry (E.A., R.V., Z.D., J.U.), and Department of Pharmacology (P.A.), Faculty of Medicine, Palacky University, Olomouc, Czech Republic
**Running Title:** Valproic acid induces CYP3A4 and MDR1 via PXR and CAR

**To whom correspondence should be addressed:** Dr. Petr Pavek, Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy, Heyrovského 1203, Hradec Kralove, CZ-500 05, Czech Republic, Tel. +420 495-067-334; Fax. +420 495-514-373; E-mail: petr.pavek@faf.cuni.cz

Number of text pages: **38**
Number of figures: **8**
Number of references: **50**
Number of words in Abstract: **239**
Number of words in Introduction: **727**
Number of words in Discussion: **1573**

**Non-standard abbreviations:** CYP, cytochrome P450; kb, kilobase(s); NR, nuclear receptor; RT-PCR, reverse transcriptase polymerase chain reaction; PXR, pregnane X receptor; CAR, constitutive androstan receptor; RXRα, 9-cis retinoic acid receptor-α; DMSO, dimethyl sulfoxide; DR3, direct repeat 3; ER6, everted repeat 6; XREM, xenobiotic-responsive enhancer module; PXRE, PXR response element; PBREM, phenobarbital responsive enhancer module; EMSA, electrophoretic mobility shift assay, VPA, valproic acid; Rif, rifampicin
Abstract

In our study, we tested the hypothesis whether valproic acid (VPA) in therapeutic concentrations has potential to affect expression CYP3A4 and MDR1 via constitutive androstane receptor (CAR) and pregnane X receptor (PXR) pathways. Interaction of VPA with CAR and PXR nuclear receptors was studied employing luciferase reporter assays, real time RT–PCR, EMSA, and analysis of CYP3A4 catalytic activity. Using transient transfection reporter assays in HepG2 cells, VPA was recognized to activate CYP3A4 promoter via CAR and PXR pathways. By contrast, significant effect of VPA on MDR1 promoter activation was observed only in CAR co-transfected HepG2 cells. These data well correlated with up-regulation of CYP3A4 and MDR1 mRNAs analyzed by real time RT-PCR in cells transfected with expression vectors encoding CAR or PXR and treated with VPA. Additionally, VPA significantly up-regulated CYP3A4 mRNA in primary hepatocytes and augmented the effect of rifampicin. EMSA experiments showed VPA-mediated augmentation of CAR/RXRα heterodimer binding to DR3 and DR4 responsive elements of CYP3A4 and MDR1 genes, respectively. Finally, analysis of specific CYP3A4 catalytic activity revealed its significant increase in VPA-treated LS174T cells transfected with PXR. In conclusion, we provide novel insight into mechanism, by which VPA affect gene expression of CYP3A4 and MDR1 genes. Our results demonstrate that VPA has potential to up-regulate CYP3A4 and MDR1 through direct activation of CAR and/or PXR pathways. Furthermore, we suggest that VPA synergistically augments the effect of rifampicin in transactivation of CYP3A4 in primary human hepatocytes.
Valproic acid (VPA) is an effective broad-spectrum anticonvulsant used in the treatment of primary generalized tonic-clonic, absence, and partial seizures (Tanaka, 1999). VPA has recently been identified as an inhibitor of histone deacetylase (HDAC) with potential antitumorous activity that has been studied in several clinical trials (Gottlicher et al., 2001; Blaheta et al., 2002; Kramer et al., 2003; Blaheta et al., 2005; Raffoux et al., 2005). VPA is well known to affect mechanisms that control drug disposition such as activity of hepatic biotransformation enzymes or drug binding to plasma proteins (Rogiers et al., 1995; Wen et al., 2001; Perucca, 2006). Generally, VPA is thought to be an inhibitor rather than inducer of drug metabolizing enzymes (Perucca, 2006). However, this point of view is currently not supported satisfactorily by comprehensive data published in literature. Regarding metabolizing enzymes of cytochrome P450 family (CYPs), Wen and coworkers have demonstrated using in vitro methods that VPA in therapeutically relevant concentrations competitively inhibits only human CYP2C9 catalytic activity (Wen et al., 2001). On the other hand, there is clear evidence that VPA has potential to up-regulate expression and activity of several rodent and human genes encoding proteins involved in drug disposition. It was found that prolonged exposure of rats to VPA results in the self-inducing metabolism of the agent (Fisher et al., 1991). Moreover, Rogiers and colleagues have found VPA to be a potent inducer of genes of the rat Cyp2b subfamily; in particular Cyp2b1 and Cyp2b2 (Rogiers et al., 1992; Rogiers et al., 1995). Recently, Eyel and colleagues have found out that VPA does not affect expression of rat Cyp3a2, an orthologue of human CYP3A4; whereas valpromide, the primary amid of VPA that reveals no HDAC inhibitory activity, was shown to induce this gene by a nonspecific mechanism (Eyal et al., 2006). Additionally, these authors have suggested that VPA induces expression and activity of human P-glycoprotein (P-gp, MDR1), a member of the ABC family of drug transporters, in tumor cell lines by mechanism of HDAC inhibition (Eyal et al., 2006). These summarized data indicate that VPA is capable to alter...
expression and activity of various CYPs differently. Moreover, VPA has potential to induce MDR1 gene.

We assumed that alteration of expression of these genes could be caused by interaction of VPA with constitutive androstane receptor (CAR; N113) and human pregnane X receptor (PXR; SXR; NR1I2). PXR and CAR are ligand-activated nuclear receptors that as heterodimers with retinoid X receptor α (RXRα) up-regulate the transcription of their target genes, such as CYP3A4 and MDR1, by interaction with specific promoter binding motifs (Goodwin et al., 1999). PXR has been shown to be activated by many structurally and chemically diverse ligands. Examples of human PXR activators include xenobiotics such as rifampicin (Bertilsson et al., 1998; Pascussi et al., 2000), the endobiotics lithocholic acid (Staudinger et al., 2001; Xie et al., 2001), progesterone metabolite 5-pregnane-3,20-dione (Jones et al., 2000), and the herbal compound hyperforin (Moore et al., 2000a). In the case of CAR, the experimental substance CITCO, the antimalarial artemisinin drugs, and 5-pregnane-3,20-dione have been recognized as its ligands (Jones et al., 2000; Maglich et al., 2003; Burk et al., 2005b). The barbiturate drug phenobarbital activates CAR indirectly through the increase of CAR translocation from the cytoplasm to the nucleus (Honkakoski et al., 1998; Kawamoto et al., 1999; Goodwin and Moore, 2004). On the other hand, several competitive inverse agonists of CAR have also been discovered such as androstanol, androstenol and clotrimazole (Forman et al., 1998; Moore et al., 2000b).

In this study, we examined whether VPA controls expression of CYP3A4 and MDR1 genes at the transcriptional level via activation of PXR and CAR pathways. This hypothesis was investigated in the human Caucasian hepatocyte carcinoma (HepG2) and human colon carcinoma (LS174T) cells using several reporter luciferase constructs with major promoter regulatory sequences of CYP3A4 and MDR1. In addition, employing real time RT-PCR, we investigated CYP3A4 mRNA expression in primary human hepatocytes treated with VPA.
Additionally, we studied whether VPA augments binding of CAR/RXRα to several response elements of CYP3A4 (DR3, ER6) and MDR1 (DR4) using Electrophoretic Mobility Shift Assay (EMSA).

Our data indicate that VPA is capable to transactivate both CYP3A4 and MDR1 via interaction with CAR pathway; however, VPA-mediated activation of PXR pathway controls only CYP3A4 gene expression. Moreover, we demonstrate that VPA synergizes with rifampicin in transactivation of CYP3A4 in primary human hepatocytes.
Methods

Cell Lines and Chemicals. The human Caucasian hepatocyte carcinoma HepG2 and human colon adenocarcinoma LS174T cell lines were purchased from the European Collection of Cell Cultures (ECACC, Salisbury, UK) and were used within 25 passages after delivery and maintained in antibiotic-free DMEM supplemented with 10% fetal calf serum (FCS), 1% sodium pyruvate and 1% nonessential amino acids (Sigma-Aldrich). The latter cell line has been previously shown to have highly inducible expression of CYP3A4 and MDR1 (Geick et al., 2001).

Androstenol (5α-androst-16-en-3α-ol), rifampicin, VPA (2-propylpentanoic acid) and DMSO (dimethyl sulphoxide) were purchased from Sigma-Aldrich. CITCO ((6-(4-chlorophenyl) imidazo [2,1-b][1,3] thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl) oxime was purchased from BIOMOL (Plymouth Meeting, PA). DMSO or water was used as a solvent of VPA when indicated.

Plasmids. A chimeric \textit{p3A4-luc} reporter construct containing the basal promoter (–362/+53) with proximal PXR response element (PXRE) and the distal xenobiotic-responsive enhancer module (XREM) (–7836/–7208) of the CYP3A4 gene 5′-flanking region inserted to pGL3-Basic reporter vector was described by Goodwin et al. (Goodwin et al., 1999). Plasmid p-7975(Δ7012–1804) harboring the enhancer of MDR1 gene 5′-flanking region (MDR1E) and the basal promoter was inserted in pGL3-Basic reporter vector as described by Geick et al. (2001), herein it is referred to as \textit{pMDR1-luc}. \textit{pMDR1E-SV40-luc} reporter plasmid was constructed by insertion of the enhancer region of MDR1 gene from –7881 to –7809 into pGL3-Promoter plasmid (Promega, Madison, WI) in \textit{NheI/BglII} cloning sites upstream of a heterologous promoter SV40. CYP2B6 PBREM reporter gene construct (\textit{pPBREM-SV40-luc}) containing two DR4-type motives (NR1 and NR2) was prepared from \textit{pGL3-Promoter}
plasmid by insertion of the region from -1733 to -1683 of CYP2B6 promoter into NheI/BglII cloning sites upstream of a heterologous promoter SV40. Constructed plasmids were sequenced using a Big Dye Terminator Cycle Sequencing Method (Applied Biosystems, MD). The expression plasmid for human PXR receptor, *pSG5-PXR*, was kindly provided by Dr. S. Kliewer (University of Texas, Dallas, TX). The human CAR expression plasmid *pCR3-CAR* was kindly provided by Dr. M. Negishi (NIEHS, Research Triangle Park, NC). The expression plasmid *pSG5-hRXRα* encoding hRXRα cDNA was a generous gift from Dr. C. Carlberg (University of Kuopio, Finland).

**Transient Transfection and Luciferase Gene Reporter Assays.** All transfection assays were carried out using Lipofectamine®2000 transfection reagent (Invitrogen, Carlsbad, CA) in cells cultivated in the phenol red-free medium containing 10% charcoal-stripped FCS, 1% sodium pyruvate and 1% nonessential amino acids according to the manufacture’s instruction. HepG2 cells (2 × 10⁵) were seeded into 48-well plates and co-transfected with a luciferase reporter construct (0.4 µg/well) and expression plasmid encoding either CAR or PXR (50 ng/well) 24 h later. Subsequently, cells were maintained in medium supplemented with 10% charcoal/dextran-stripped FBS containing VPA (Sigma-Aldrich) at appropriate concentration for 24 h. Luminescence activity was determined with a luminometer Genios Plus (Tecan, Grödig, Austria) in cell lysate using a commercially available luciferase detection system (Promega, Madison, WI). Additionally, all experiments were in parallel performed using empty *pGL3-Basic* and *pGL3-Promoter* luciferase reporter constructs containing no responsive elements to distinguish non-specific CAR- and PXR- independent effect of VPA on reporter plasmids used. Luminescence of these samples were taken as background that was subtracted in final calculation from luminescence of cell samples transiently transfected with reporter plasmids containing response elements of tested genes.
Resulting data are presented as ratio of luminescence of treated cell samples to control. Luminescence of each sample has been normalized to its protein concentration determined with BCA system (Pierce, Milwaukee, WI).

**Real Time RT-PCR Analysis of CYP3A4 mRNA.** LS174T cells \((1.2 \times 10^5)\) were seeded into 24-well plates and cultivated for 24 h. Then cells were transfected with CAR or PXR expression plasmids (400ng/well) and appropriate cell samples were exposed to VPA at a concentration of 500 µM for 48 h. Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. The following primers were used for CYP3A4 (forward primer: 5'-TTCAGCAAGAAGCAACAGAAGACCA-3'; reverse primer: 5'-GGTTGAAGAAGTCCTCCTAAGC-3'), for MDR1 (forward primer: 5'-TGCTCAGCACAGGATGTGAGTG-3'; reverse primer: 5'-AATTACAGCAAGCCTGAACC-3') and for housekeeping genes HPRT (Hypoxanthine-Guanine Phosphoribosyl Transferase) (forward primer: 5'-CTGGAAAGAATGTCTTGATTGTG-3'; reverse primer: 5'-CTGGAAAGAATGTCTTGATTGTG-3'; reverse primer: 5'-TTTGGATTATACTGCCTGAAGCA-3') and for B2M (β2-microglobulin) (forward primer: 5'-CGTGTAACCACATGTGACTTGGC-3'; reverse primer: 5'-CATCTTCAAACCTCCATGATG-3'). cDNA was prepared from 1 µg of total RNA with MMLV transcriptase (Finnzymes, Finland) using oligo(dT)\(_{15}\)VN primer (Generi-Biotech, Hradec Králové, Czech Republic) and porcine RNase inhibitor (TaKaRa, BIO, Shiga, Japan). Real-Time PCR analysis was performed on an iCycler (Bio-Rad, Hercules, CA). cDNA (40 ng reverse transcribed RNA) was amplified with HotStar Taq polymerase (QIAGEN, Valencia, CA) under the following conditions: 3 mM MgCl\(_2\), 0.2 mM dNTP, 0.3 µM each primer, 0.025 U/µl polymerase, SybrGreen I in 1:100,000 dilution and fluorescein (10 nM); the temperature profile was 95°C for 14 min; 50 times: 95°C for 15 s, 60 °C for 20 s, 72 °C
for 30 sec; 72 °C for 15 sec; melting curve program 70-95°C. All samples were run in triplicates simultaneously with negative controls. The processing of real-time amplification curves was performed on iCycler software ver. 4.6 (Bio-Rad). Pfaffl’s method was applied for relative quantification of gene expression normalized to endogenous control (housekeeping) gene (Pfaffl, 2001). Results are presented as the means of at least three experiments.

**Isolation and CYP3A4 mRNA Analysis in Primary Cell Culture of Human Hepatocytes.**

Human tissue samples were obtained according to protocols approved by the Local ethics committee of the Palacky University in Olomouc complying with the current Czech legislation. Hepatocytes were prepared from lobectomy segments resected from adult patients for medical reasons unrelated to our research program. The tissue encompassing the tumor was dissected by a surgeon and sent for anatomopathological studies, while the remaining tissue was used for hepatocytes preparation. No information on the patients was available to us, apart from age, sex, and the reason for surgery. Human liver samples used in this study were obtained from two donors: Donor 1, woman, 69 years old, tumor metastasis; donor 2, woman 46 years old, Caroli syndrome. Hepatocytes were isolated as previously described (Pichard-Garcia et al., 2002). Following isolation, the cells were plated on collagen-coated culture dishes at density $1.4 \times 10^5$ cells/cm$^2$. Culture medium was enriched for plating with 2% FCS (v/v) as described previously (Isom et al., 1985). The medium was replaced with serum-free medium the day after and the cells were allowed to be stabilized for additional 48 – 72 h prior to the treatment with VPA (500 µM) or rifampicin (10 µM) or their combination. Cells were maintained at 37 °C and 5% CO$_2$ in a humidified incubator. Effect of VPA on CYP3A4 mRNA expression was tested in periods of 24 and 48 h. Effect of rifampicin and the combination of VPA and rifampicin were studied in period of 24 h. In the later experiments, DMSO (0.1%) was used as solvent of both VPA and rifampicin. Level of CYP3A4 mRNA
expression was analyzed employing real time RT-PCR according to protocol mentioned above.

**Functional Analysis of CYP3A4 Activity.** LS174T cells (6 × 10⁵) were seeded into 12-well plates and cultivated for 24 h. Subsequently cells were transfected with CAR or PXR expression plasmids (1.2 µg/well) and then exposed to VPA at a concentration of 600 µM for 48 h. After treatment, cells were washed with PBS and cultivated in serum-free Opti-MEM medium (Gibco) containing testosteron at a final concentration of 150 µM for two h at 37 °C. Then, cells were washed with PBS and lysed with 200 µl SDS (1 %). CYP3A4 activity was detected in total cellular lysate (150 µl) using an established method based on the measuring of a prototypic CYP3A4-mediated testosterone 6β-hydroxylation activity (Guengerich et al., 1986) and modified for the analysis of the metabolite in cell lysate. For the determination of CYP3A4 activity, the metabolite was extracted to dichloromethane. Subsequently, the solvent was evaporated and the sample dissolved in the mobile phase. Concentration of the testosterone metabolite was determined using a Shimadzu Class VP HPLC system (Shimadzu, Tokyo, Japan). Final activity was normalized to sample protein concentration in cell lysate that was measured using BCA assay according to manufacture’s instructions (Pierce, Milwaukee, WI).

**Electrophoretic Mobility Shift Assay (EMSA).** Human CAR and RXRα were translated in vitro using TNT® Quick Coupled Transcription/Translation Systems (Promega, Delta House, Southapton, USA). The nuclear fraction was isolated from HepG2 cells transfected with hRXRα expression vector using CelLytic™ NuCLEAR™ Extraction Kit (Sigma, Saint Louis, Missouri, USA). The following double-stranded 5'–biotinylated oligonucleotides of specific response elements of both CYP3A4 and MDR1 promoters were used as probes: CYP3A4
DR3 sense, 5'-GAA TGA ACT TGC TGA CCC TCT-3'; CYP3A4 DR3 antisense, 5'- AGA GGG TCA GCA AGT TCA TTC-3'; CYP3A4 ER6 sense, 5'-ATA TGA ACT CAA AGG AGG TCA GTG-3'; CYP3A4 ER6 antisense, 5'-CAC TGA CCT CTT GTG AGT TCA TAT-3'; MDR1 DR4 sense, 5'-CAT TGA ACT AAC TTG ACC TTG C-3' and MDR1 DR4 antisense, 5'-GCA AGG TCA AGT TAG TTC AAT G-3'. The oligonucleotides were synthesized in Generi Biotech, s.r.o. (Hradec Kralove, Czech Republic).

EMSA method was performed according to the protocol published previously with slight modifications (Frank et al., 2003). The binding reactions were performed in a total volume of 20 µl and contained equal amounts (~ 3 µg) of CAR and RXRα, 10x Binding Buffer (100 mM Tris, 500 mM KCl, 10 mM DTT) (Pierce, Milwaukee, WI), Poly (dI·dC) Double Strand (GE Amersham Biosciences, Piscataway, NJ) and 1% NP-40. VPA was tested at final concentrations of 100, 500 and 1000 µM. CITCO, an agonist of human CAR, was used at the concentration of 6.25 µM, androstenol at the concentration of 10 µM. DMSO was used as a solvent of the compounds at maximal final concentration of 0.1%. For supershift experiments, 1 µg of the anti-RXRα rabbit polyclonal IgG antibody was added to the reaction mixture (Santa Cruz Biotechnology, Inc., California, USA). Reactions were preincubated on ice for 10 min before the addition of oligonucleotide probe (20 fmol). Samples were maintained at room temperature for an additional 20 min, and then protein/DNA complexes were resolved on a 5% (w/v) non-denaturing polyacrylamide gel (acrylamide/bisacrylamide 29:1 w/v) in 0.5x TBE buffer (450 mM Tris, 450 mM Boric Acid, 10 mM EDTA). The gels were electrophoresed at 100 V for an h at room temperature. Next, the gels were blotted at 380 mA for 30 min at 4°C and then analyzed by Chemiluminescent Nucleic Acid Detection Module (Pierce, Milwaukee, WI).
EMSA Quantification. EMSA reactions were exposed to X-ray film (Foma Bohemia a.s, Hradec Králové, Czech Republic) and then bands were quantified using computerized densitometry using LabImage densitometry analysis software (Kapelan, Gemany).“

Statistics. One-way ANOVA followed by the Dunnett's Multiple Comparison post hoc test or unpaired Student’s t-test were used for statistical analysis of data using a GraphPad Prism software. Two-way ANOVA with interaction was used to analyze synergistic effect of VPA and rifampicin.
Results

Effect of VPA on CAR- and PXR-mediated Activation of CYP3A4 Promoter in HepG2 Cells Transiently Transfected with p3A4-luc Luciferase Reporter Construct. First, we examined whether VPA affects activation of p3A4-luc reporter construct through CAR and PXR. We observed statistically significant concentration-dependent increase in CAR- and PXR-mediated transcriptional activation of p3A4-luc in HepG2 cells after 24 h exposure to VPA (Fig. 1). VPA at the concentration of 500 µM doubled the activation of p3A4-luc in cells co-transfected with CAR expression vector (Fig. 1). In HepG2 cells co-transfected with PXR, we observed even a 4-fold increase in activation of p3A4-luc after treatment with VPA (500 µM) (Fig. 1). In contrast, VPA did not significantly affect transcriptional activation of p3A4-luc in HepG2 cells, which were not co-transfected with either CAR or PXR (Fig. 1). We observed that expression of both CAR and PXR in HepG2 cells in the absence of an exogenous ligand resulted in statistically significant activation of p3A4-luc reporter, which is in agreement with published data and indicates involvement of endogenous activators of the nuclear receptors in HepG2 cells (Fig. 1) (Goodwin et al., 1999; Goodwin et al., 2002).

Transactivation of CYP3A4 Promoter by VPA in Combination with CITCO or Rifampicin. In these experiments, we examined whether VPA has the ability to affect CAR- and PXR-mediated activation of p3A4-luc construct caused by prototypic ligands CITCO (500 nM) in CAR- and Rifampicin (10 µM) in PXR-expressing cells. VPA at tested concentrations in combination with CITCO (500 nM) significantly augmented CAR-mediated activation of p3A4-luc compared to CAR expressing cells treated with CITCO (p<0.01) (Fig. 2). Similarly, we observed more pronounced effect of VPA in combination with rifampicin (10 µM) on transcriptional activation of p3A4-luc via PXR compared to the effect of rifampicin alone (p< 0.05) (Fig. 2).
Effect of VPA on CAR- and PXR-mediated Activation of MDR1 Promoter in HepG2 Cells Transiently Transfected with pMDR1-luc or Heterologous pMDR1E-SV40-luc Luciferase Reporter Constructs. Regarding MDR1, two different luciferase reporter constructs were employed in our study. First, we used pMDR1-luc construct containing the distal enhancer region with DR4 responsive motif common for both PXR- and CAR-mediated transactivation of MDR1 gene, and the native basal promoter from -1803 to +281. Using this reporter construct, we observed similar effect of VPA on activation of MDR1 promoter in cells co-transfected with PXR or CAR in comparison with mock-transfected HepG2 cells (Fig. 3A). On the other hand, rifampicin (10 µM) and CITCO (1 µM) significantly activated (∼2-fold, \(p<0.05\)) the pMDR1-luc construct in HepG2 cells cotransfected with PXR or CAR expression plasmids under used experimental conditions. This indicates that VPA has probably potential to transactivate this luciferase construct independently on PXR and CAR pathways through a nonspecific mechanism, which is likely related to activation of MDR1 basal promoter (Morrow and Nakagawa, 1994).

In the light of our previous observations demonstrating that heterologous pMDR1E-SV40-luc is more responsive to both PXR- and CAR-mediated activation than pMDR1-luc reporter, we performed transfection assay with pMDR1E-SV40-luc reporter construct containing the MDR1 enhancer upstream of viral SV-40 promoter. Employing the plasmid, we observed that VPA at a concentration of 500 µM activates significantly only CAR-mediated transcription of pMDR1E-SV40-luc reporter construct (\(p<0.001\)) (Fig. 3B). The effect of VPA on activation of pMDR1E-SV40-luc plasmid was comparable with the effect of CITCO (1 µM, 2-fold activation) and with rifampicin (25 µM, 2.3-fold activation, \(p<0.05\)) in nuclear receptor-transfected cells.

Finally, we used androstenol, an inverse agonist of CAR, to confirm that VPA activates pMDR1E-SV40-luc through CAR. Androstenol (10 µM) significantly repressed CAR-
mediated transcriptional activation of \textit{pMDRIE-SV40-luc} in cells exposed to VPA at a concentration of 500 \(\mu\)M \((p<0.05)\) (Fig. 3C). In contrast, we observed no effect of androstenol on pGL3-Basic or pGL3-Promoter constructs activities in cells co-transfected with CAR expression vector (data not shown).

**Effect of VPA on CAR- and PXR-mediated Activation of CYP2B6 PBREM in HepG2 Cells Transiently Transfected with \textit{pPBREM-SV40-luc} Luciferase Reporter Construct.**

To elucidate discrepancy between CAR- and PXR-mediated activation of MDR1 promoter by VPA, we analyzed luciferase activity of \textit{pPBREM-SV40-luc} construct in cells transiently transfected with CAR or PXR expression vectors and exposed to VPA (500 \(\mu\)M). \textit{pPBREM-SV40-luc} construct contains two DR4-type responsive elements of the phenobarbital responsive enhancer module (PBREM) of CYP2B6 gene, which has high ability to interact with both CAR and PXR (Goodwin et al., 2001; Faucette et al., 2006). We detected significant up-regulation of \textit{pPBREM-SV40-luc} activity in HepG2 cells co-transfected with both CAR and PXR expression plasmids \((p<0.001, \text{Fig. 4})\). Moreover, the activation of the construct was further significantly augmented in cells co-expressing CAR and exposed to VPA (5.8-fold increase, \(p<0.001\), Fig. 4). Similarly, VPA increased significantly activation of \textit{pPBREM-SV40-luc} in PXR expressing cells (2-fold, \(p<0.05\)). Under the same experimental conditions, CITCO (1 \(\mu\)M) increased activation of the plasmid 2.1-fold in the cells expressing CAR and rifampicin (10 \(\mu\)M) 2.4-fold in PXR-transfected cells. Nevertheless, we also detected comparable activation of the luciferase construct by VPA in cells with no exogenous PXR \((p<0.05)\) (Fig. 4), which documents that exogenous PXR has minor or no effect in activation of \textit{pPBREM-SV40-luc} by VPA. Thus, we observed a similar pattern in activation of \textit{pPBREM-SV40-luc} and \textit{pMDRIE-SV40-luc} by VPA (Fig. 3B and 4). In both cases, we
demonstrated that VPA increases CAR-mediated, but not PXR-mediated transactivation of the constructs.

**Analysis of VPA-mediated Up-Regulation of CYP3A4 and MDR1 mRNAs in LS174T Cells.** To evaluate the ability of VPA to induce CYP3A4 and MDR1 mRNA levels by means of CAR and PXR activation, real time RT-PCR was employed. CYP3A4 and MDR1 mRNAs were quantified in samples of LS174T cells transfected with expression plasmids encoding studied nuclear receptors and exposed to VPA for 48 h. Significant effect of VPA on CYP3A4 mRNA level was observed in cells transfected with both CAR and PXR nuclear receptors yielding a 4.2-fold and 3.8-fold ($p<0.001$ and $p<0.01$) induction, respectively (Fig. 5A). VPA also significantly up-regulated CYP3A4 mRNA in LS174T cells, which were not co-transfected with any nuclear receptor ($p<0.01$) (Fig. 5A). This might be in agreement with high expression of endogenous PXR in LS174T cells, which could at least partly participate in up-regulation of CYP3A4 mRNA by VPA (data in Fig. 1) (Burk et al., 2005b).

In case of MDR1, we observed similar profile of VPA-mediated MDR1 mRNA up-regulation. Contrary to transfection assays, we detected statistically significant effect of VPA on MDR1 mRNA expression in PXR transfected LS174T cells (2.0-fold increase, $p<0.05$). However, the MDR1 mRNA level was not statistically significantly different from the level in VPA-treated cells (Fig. 5B). Thus, we suppose that the increase in MDR1 mRNA level after treatment with VPA is caused mostly by mechanism of HDAC inhibition described previously rather than through activation of PXR pathway by VPA (Morrow and Nakagawa, 1994; Jin and Scotto, 1998; Xiao and Huang, 2005). Importantly, we observed statistically significant ($p<0.05$) up-regulation of MDR1 mRNA after co-transfection of LS174T cells with CAR expression vector and treatment with VPA (Fig. 5B). On the other hand, co-transfection of LS174T cells with expression plasmid for either PXR or CAR without exposure to VPA did not result in statistically significant up-regulation of CYP3A4 and MDR1 mRNAs (Fig. 5A and 5B).
Under the same experimental conditions, treatment of LS174T cells with rifampicin (10\(\mu\)M) resulted in 12-fold increase in CYP3A4 mRNA and 7-fold increase in MDR1 mRNA.

**Determination of CYP3A4 Catalytic Activity in LS174T Cells Exposed to VPA (600 \(\mu\)M).** CYP3A4 induction was subsequently investigated employing functional assay based on determination of specific CYP3A4-mediated testosterone 6\(\beta\)-hydroxylation activity measured in LS174T cell lysate. As shown in Fig. 6, only cells transfected with plasmid encoding PXR yielded statistically significant increase in CYP3A4 catalytic activity after 48 h exposure to VPA at a concentration of 600 \(\mu\)M (\(p<0.05\)).

**VPA induces CYP3A4 mRNA in primary human hepatocytes and synergizes with the effect of rifampicin.** To determine whether VPA induces CYP3A4 mRNA and whether it influences the induction by the rifampicin, primary culture of human hepatocytes were treated individually or in combination with VPA (500 \(\mu\)M) and/or rifampicin (10 \(\mu\)M). CYP3A4 mRNA was significantly up-regulated in the hepatocytes exposed to VPA for 48 h taken from both donor 1 (14.1-fold, \(p<0.01\)) (Fig. 7A) and donor 2 (3.8–fold, \(p<0.01\)) (Fig.7B). As shown in the Fig 7C, employing unpaired Student’s \(t\)-test, we revealed statistically significant increase of CYP3A4 mRNA compared to control treated with DMSO (0.1\%\) in cell samples treated with rifampicin (10 \(\mu\)M) for 24 h (donor 1 - 20.1 and donor 2 - 13.6-fold, respectively; \(p<0.001\)). In cells cultivated in medium containing VPA (500 \(\mu\)M) and vehiculum (DMSO 0.1\%) used for elimination of rifampicin solvent effect, we also detected significant induction of CYP3A4 mRNA relative to control (DMSO 0.1\%) (\(p<0.01\) and \(p<0.05\), respectively). Furthermore, when VPA (500 \(\mu\)M) and rifampicin (10 \(\mu\)M) were added simultaneously into medium and hepatocytes were cultivated for 24 h, up-regulation of CYP3A4 was synergistic rather than additive (62 and 34 –fold). Employing two-way
ANOVA, this synergy was found to be statistically significant at the level of $p<0.01$ (Fig. 7C).

Examination of Interactions between CAR/RXR$\alpha$ Heterodimer or CAR Monomer and Responsive Elements of CYP3A4 and MDR1 Promoters in the Presence of VPA Employing a Ligand-dependent EMSA. The interactions between CAR/RXR$\alpha$ heterodimers and nuclear receptor-binding motives of CYP3A4 (DR3, ER6) and MDR1 enhancer (DR4) in the presence of VPA were examined employing EMSA using in vitro-translated CAR and RXR$\alpha$ proteins. CAR forms complex with RXR$\alpha$, which binds DR3, DR4 and ER6 responsive elements of CYP3A4 and MDR1 even in the absence of a ligand (Goodwin et al., 1999; Geick et al., 2001; Goodwin et al., 2002; Burk et al., 2005a). This complex formation can be enhanced by ligand binding to CAR, which can be revealed employing EMSA (Frank et al., 2004). We detected that VPA at tested concentrations of 500 and 1000 $\mu$M increased the formation of CAR/RXR$\alpha$ complex with DR3 responsive element of CYP3A4 promoter (Fig. 8A lane 8; B, lanes 6 and 7). Fig. 8A shows that employing recombinant CAR and RXR$\alpha$ proteins, VPA moderately (by $\sim 30\%$) augmented the CAR/RXR$\alpha$/DR3 complex in EMSA experiments (Fig. 8A, lane 8). In the next experiments, we used nuclear fraction from HepG2 cells transfected with expression vector encoding RXR$\alpha$. VPA at the concentration of 500 $\mu$M augmented the complex 1.8-fold and at the concentration of 1000 $\mu$M VPA increased 4.2-fold binding of CAR/RXR$\alpha$ to DR3 (Fig. 8B, lane 6 and 7). Similarly, as shown in Fig. 8D (lane 6), we detected increased ($\sim 1.5\text{-fold}$) binding of CAR/RXR$\alpha$ heterodimer to oligonucleotide containing DR4 motive of MDR1 enhancer in the presence of VPA (1000 $\mu$M). Consistently, CITCO, an agonist of human CAR, augmented binding of CAR/RXR$\alpha$ complex to DR3 response elements (Fig. 8A, lane 5; 8B, lane 3) (Maglich et al., 2003). The inverse agonist of CAR androstenol (10 $\mu$M) decreased formation of CAR/RXR$\alpha$ complex with response element DR3 in samples treated with CITCO (500 nM) or VPA (500 and 1000 $\mu$M) (Fig. 8A,
B, C, D). Interestingly, we observed that VPA at tested concentrations augments interaction of recombinant CAR monomer with DR3 motive of CYP3A4 promoter (Fig. 8C, lane 2). On the other hand, we did not detect any significant and reproducible effect of VPA on interaction of CAR/RXRα heterodimer with ER6 response element of CYP3A4 gene (data not shown). RXRα alone did not reveal any interaction with tested response elements (data not shown). Similarly, we did not detect any complex after incubation of nuclear fraction of HepG2 cells and recombinant RXRα with DR3 oligonucleotide under used conditions (data not shown).

These data suggest that VPA could directly interact with CAR/RXRα heterodimer and CAR monomer in binding with DR3 and DR4 response elements of CYP3A4 and MDR1.

Unfortunately, there is no report in literature, which introduce reliable ligand-dependent EMSA assay with recombinant PXR at present. Therefore, we could not analyze interaction of VPA with PXR/RXRα complex at present using EMSA method.
Discussion

VPA, an effective broad-spectrum anticonvulsant, has been shown to affect expression of a large number of genes (Bosetti et al., 2004). Some of these recognized alterations in gene expression have been attributed to HDAC inhibitory activity of VPA (Chen et al., 1999; Phiel et al., 2001; Werling et al., 2001; Eyal et al., 2006). In this study, we show for the first time that VPA is capable in clinically relevant range of concentrations < 1000 µM (Centorrino et al., 2003; Allen et al., 2006; Davis et al., 1994; Wen et al., 2001) to up-regulate CYP3A4 and MDR1 genes expression also by a different molecular mechanism via direct activation of CAR pathway. Moreover, we demonstrate that VPA can increase CYP3A4 gene expression and activity through activation of PXR nuclear receptor as well.

Ligand-activated nuclear receptors CAR and PXR up-regulate expression of target genes at the transcriptional level through interaction with specific promoter response elements. Therefore, in order to examine the potential effect of VPA on CAR- and PXR-mediated transcriptional regulation of CYP3A4 and MDR1 genes, we first employed transient transfection experiments with luciferase reporter constructs containing relevant regulatory promoter sequence of tested genes (Goodwin et al., 1999; Goodwin et al., 2001; Goodwin et al., 2002; Burk et al., 2005a). Using transient transfection, we established that the reporter constructs appeared in cells separately from the chromosomal DNA and nucleosome structure, which guaranteed that detected effect of VPA on activation of luciferase constructs is independent on chromatin remodeling caused by VPA-mediated HDAC inhibition.

We demonstrate that VPA induces CAR- and PXR-mediated transactivation of \( p3A4\text{-}luc \) construct containing both DR3 and ER6 responsive elements of CYP3A4 required for CAR- and PXR-mediated regulation of the gene (Goodwin et al., 1999) (Fig. 1). Interestingly, we found out that the combination of VPA with prototypic ligands causes far more pronounced transactivation of the \( p3A4\text{-}luc \) construct (Fig. 2). These data indicate synergistic effect of
VPA and rifampicin on transactivation of CYP3A4 via PXR, which could play an important role during co-treatment with these drugs.

In additional experiments, we examined activation of two different luciferase reporter constructs containing MDR1 enhancer and either native or viral SV40 basal promoter (Burk et al., 2005a). We did not detect any significant CAR- or PXR-dependent effect of VPA on activation of MDR1 gene promoter in HepG2 cells transfected with pMDR1-luc reporter construct, although increase in transcriptional activation of this reporter construct was observed in cells exposed to VPA (Fig. 3A). On the other hand, employing pMDRIE-SV40-luc reporter construct containing the MDR1 enhancer upstream of SV-40 viral promoter, VPA was identified as an activator of the MDR1 enhancer via CAR pathway (Fig. 3B). Thus, by using of pMDRIE-SV40-luc construct we eliminated potential interference of additional transcriptional factors that bind relevant sites in the basal promoter of MDR1 gene such as NF-Y, Sp1, AP-1, NK-κB, C/EBPβ etc. (Scotto, 2003) and analyzed specific CAR-/PXR-mediated activation of the MDR1 enhancer by VPA. Moreover, the reporter plasmid lacks inverted CCAAT motive (Y-box), which was shown to be essential for activation of MDR1 promoter in transient transfection reporter assays by several other HDAC inhibitors (Jin and Scotto, 1998). Despite this fact, significant activation of pMDRIE-SV40-luc reporter construct by VPA was observed also in the absence of co-transfected CAR or PXR, which indicates that VPA can also activate MDR1 enhancer of pMDRIE-SV40-luc reporter construct (Fig. 3B). We suppose that endogenous CAR or PXR are not involved in the phenomenon as their functional expression in HepG2 cells is very low. However, we cannot exclude potential up-regulation of various transcriptional factors by VPA treatment, which could lead to transactivation of the reporter construct.

Subsequently, interaction of VPA with PXR transactivation pathway has been studied in more detail using another gene reporter construct pPBREM-SV40-luc containing two DR4-
type motives of CYP2B6 PBREM region upstream of SV-40 viral promoter, which were recently demonstrated to have a high affinity to both PXR and CAR (Faucette et al., 2006). These experiments have revealed significant CAR-mediated, but no PXR-mediated activation of pPBREM-SV0-luc reporter construct by VPA, which is in agreement with the findings obtained employing of pMDRI-SV40-luc reporter construct. Thus, we suggest different effect of VPA on CAR- and PXR-mediated transcriptional activation of heterologous reporter constructs pPBREM-SV40-luc and pMDRI-SV40-luc in comparison with p3A4-luc construct (Fig. 1, 3B, 4). We hypothesize that this discrepancy can be explained considering the report of Masuyama and coworkers (Masuyama et al., 2005), who demonstrated ligand- and promoter-specific fashion of PXR-mediated transcription of CYP3A4 and MDR1 genes.

CAR- and PXR-mediated regulation of CYP3A4 and MDR1 genes expression was subsequently analyzed by real time RT-PCR in samples of LS174T cells (Fig. 5A, B). mRNA expression of the studied genes was normalized to both HPRT and B2M housekeeping genes to eliminate false interpretation potentially caused by non-specific VPA-mediated up/down-regulation of these housekeeping genes. We observed the effect of co-expressed CAR and PXR on VPA-mediated up-regulation of CYP3A4 mRNA in LS174T cells (Fig. 5A), which well correlates with the reporter experiments. In case of MDR1, mRNA level was significantly up-regulated in LS174T cells transfected with CAR expression vector, whereas VPA-mediated increase of MDR1 mRNA in PXR-expressing cells was not statistically different from non-transfected cells exposed to VPA (Fig. 5B). Considering data from gene reporter assay with pMDRIE-SV40-luc (Fig. 3A) and pPBREM-SV40-luc (Fig. 4), we assume that observed influence of VPA on MDR1 mRNA expression in LS174T cells transfected with PXR should be rather attributed to HDAC inhibitory activity of VPA, which was previously demonstrated to cause MDR1 gene up-regulation (Eyal et al., 2006). Thus, we hypothesize that the total induction of MDR1 mRNA expression in LS174T cells transfected
with CAR and PXR might be a sum of several VPA effects such as inhibition of HDAC (Eyal et al., 2006) and interaction of VPA with CAR or PXR. On the other hand, we suppose that the effect of VPA on CYP3A4 mRNA up-regulation is mediated by a transcription factor(s), as HDAC inhibition did not result in induction of human CYP3A4 or its rat homologue Cyp3a2 mRNA (Rodríguez-Antona et al., 2003; Eyal et al., 2006). Nevertheless, we hypothesize that HDAC inhibitory activity of VPA synergistically augments the effect of rifampicin in PXR-mediated up-regulation of CYP3A4 mRNA in primary human hepatocytes (Fig. 7C).

The interaction of VPA with CAR was investigated in more details using EMSA, in which interaction of VPA with CAR/RXRα heterodimer or CAR monomer (Frank et al., 2003) and responsive elements of both CYP3A4 and MDR1 promoters were examined. In the presence of VPA, we detected augmented binding of CAR/RXRα heterodimer to DR3 responsive element of CYP3A4 and to DR4 responsive element of MDR1 (Fig. 7A, B, C, D). Binding of CAR/RXRα to ER6 element of CYP3A4 was not affected by VPA (data not shown), which might correlate with low affinity of CAR/RXRα complex to bind ER6 motive and with minor role of ER6 in CAR-mediated CYP3A4 gene transactivation (Goodwin et al., 2002). Interestingly, we also observed increased binding of CAR monomer to DR3 motive of CYP3A4 promoter in the presence of VPA (Fig. 7 C, lane 2). Androstenol decreased the binding of CAR/RXRα heterodimer and CAR monomer to DR3 and CAR/RXRα heterodimer to DR4 in samples containing VPA (Fig. 7A, C, D), which provides us additional evidence that VPA transactivates CYP3A4 and MDR1 through CAR. Interestingly, we observed difference in the VPA-activated CAR/RXRα heterodimer binding to DR3 responsive element in EMSA experiments performed employing recombinant CAR and RXRα proteins (Fig. 7A, lane 8) in comparison with the experiments, where recombinant RXRα was replaced with nuclear extract from HepG2 cells transfected with expression vector encoding RXRα (Fig.
Binding of CAR/RXRα complex with recombinant in vitro translated RXRα to DR3 motive was only slightly augmented in the presence of VPA (~ 30%); however, using nuclear fraction of HepG2 cells transfected with RXRα, we observed more than 4-fold effect of VPA on the CAR/RXRα/DR3 complex formation (Fig. 7B, lane 7). Based on this finding, we hypothesize that nuclear fraction of HepG2 cells could contain another transcription cofactor involved in regulation of CAR/RXRα binding to DR3 in the presence of VPA.

Finally, we analyzed CYP3A4 enzymatic activity in LS174T cells exposed to VPA (600 µM) for 48 h. As shown in Fig. 6, significant increase of CYP3A4 activity was detected only in VPA-treated LS174T cells transfected with PXR expression vector (p<0.05). We did not detect any alteration of CYP3A4 enzymatic activity in non-transfected LS174T cells, although LS174T cells express PXR (unpublished data, Burk et al., 2005b). With respect to this fact, we suppose that CYP3A4 catalytic activity can be increased only in cells rich in PXR protein.

In conclusion, we show that VPA mediates transactivation of CYP3A4 and MDR1 genes via direct interaction with CAR nuclear receptor. Furthermore, we present that VPA up-regulates CYP3A4 and its catalytic activity through PXR. With respect to the published data on the effect of VPA in regulation of MDR1 gene expression we suggest that interaction of VPA with CAR signaling pathway together with VPA-mediated HDAC inhibition are the mechanisms involved in up-regulation MDR1 gene. As MDR1 plays an important role in multidrug resistance phenomenon (MDR), we assume that administration of VPA could lead to increase in tumor resistance against many anticancer drugs, which are transported by P-glycoprotein. Finally, our data indicate that VPA in clinically relevant concentrations during treatment of schizoaffective disorders, acute mania and refractory epilepsy, when VPA plasma concentrations range within 500-1000 µM, could cause drug-drug interactions with co-administered drugs, which are metabolized by CYP3A4.
References


Footnotes

This work was supported in part by grants from The Grant Agency of the Charles University in Prague 94/2005/C, the Czech Science Foundation (170/53/75301), and from the Ministry of Education of the Czech Republic (MSM 6198959216).
Legends for figures

Fig. 1. Effect of VPA on CAR- and PXR-mediated Transactivation of CYP3A4 Promoter. HepG2 cells were transiently transfected with p3A4-luc reporter construct containing the basal promoter (−362/+53) with proximal PXR response element and the distal xenobiotic-responsive enhancer module (XREM) (−7836−7208) of CYP3A4 (0.4 µg/well) and either pCR3-CAR or pSG5-PXR expression vector (50 ng) using Lipofectamine®2000 transfection reagent according to manufacture’s instructions. Transfected HepG2 cells were maintained in medium containing VPA at indicated concentrations for 24 h. Luciferase activities are normalized to protein concentration and expressed as fold activation of non-treated cells transfected with p3A4-luc. All means ±S.D. were calculated from quadruplicates of a representative experiment and analyzed using ANOVA followed by Dunnett’s test.

# p<0.05, ### p<0.001 – statistically different from non-treated cells transfected with p3A4-luc;
*
* p<0.05, ** p<0.01 – statistically different from VPA non-treated cells co-transfected with either pCR3-CAR or pSG5-PXR.

Fig. 2. Transactivation of CYP3A4 Promoter by VPA in Combination with CITCO or Rifampicin. HepG2 cells were transiently transfected with p3A4-luc reporter construct (0.4 µg/well) and pCR3-CAR or pSG5-PXR expression plasmid (50 ng) using Lipofectamine®2000 transfection reagent according to manufacture’s instructions and subsequently exposed to VPA in combination with CITCO (500 nM) or Rifampicin (Rif; 10 µM), prototype ligands of CAR and PXR, respectively, for 24 h. All means ±S.D. were calculated from quadruplicates of a representative experiment and analyzed using ANOVA followed by Dunnett’s test. Data are presented as fold activation of non-treated cells transfected only with p3A4-luc.
Fig. 3. Effect of VPA on CAR- and PXR-mediated Activation of Reporter Constructs of MDR1 Gene. HepG2 cells were transiently transfected with pCR3-CAR or pSG5-PXR expression plasmid (50 ng) and appropriate reporter construct (0.4 µg/well) using Lipofectamine®2000 transfection reagent according to manufacturer’s instructions. Transfected HepG2 cells were maintained in medium containing tested compounds at indicated concentrations for 24 h. (A.) Effect of VPA on CAR- and PXR-mediated transactivation of pMDR1-luc construct containing the enhancer region of MDR1 gene (-7975/-7013) and the basal promoter from -1803 to +231. (B.) VPA-mediated transcriptional activation of pMDR1E-SV40-luc construct containing the enhancer region of MDR1 gene and viral promoter SV40 in cells co-expressing exogenous CAR or PXR. (C.) Influence of androstenol (Andol), an inverse agonist of CAR, on CAR-mediated transcriptional activation of pMDR1E-SV40-luc in HepG2 cells treated with VPA. HepG2 cells were transiently transfected with pCR3-CAR (40 ng) and pMDR1E-SV40-luc construct (0.4 µg/well) using Lipofectamine®2000. Control and VPA-treated cells were exposed to DMSO (0.1 %) to eliminate influence of the androstenol solvent. Data are presented as fold activation of non-treated cells transfected only with appropriate reporter construct pMDR1E-luc or pMDR1E-SV40-luc. All means ±S.D. were calculated from quadruplicates of a representative experiment.

### p<0.001 – statistically different from non-treated cells transfected only with reporter construct; * p<0.05, ** p<0.01, *** p<0.001 – statistically different from VPA non-treated cells co-transfected with either pCR3-CAR or pSG5-PXR expression vectors; ≠ ≠ p<0.01 - statistically different from cells transfected with reporter plasmid and exposed to VPA.
Fig. 4. Effect of VPA on CAR- and PXR-mediated Activation of PBREM Region of CYP2B6 Promoter. HepG2 cells were transiently transfected with pCR3-CAR or pSG5-PXR expression plasmid (50 ng) and pPBREM-SV40-luc reporter construct containing two DR4-type motives of CYP2B6 PBREM (0.4 µg/well) using Lipofectamine®2000 transfection reagent according to manufacture’s instructions. Transfected HepG2 cells were maintained in medium containing VPA (500 µM) for 24 h. 

### p<0.001 – statistically different from non-treated cells transfected only with reporter construct; * p<0.05, *** p<0.001 – statistically different from VPA non-treated cells co-transfected with either pCR3-CAR or pSG5-PXR expression vectors.

Fig. 5. Analysis of VPA-mediated up-regulation of CYP3A4 and MDR1 mRNAs. LS174T cells were transfected with pCR3-CAR or pSG5-PXR expression plasmids (400ng/well) using Lipofectamine®2000 transfection reagent according to manufacture’s instructions and exposed to VPA (500 µM) for 48 h. mRNA expressions of tested genes were determined employing real time RT-PCR and normalized to HPRT housekeeping gene. Effect of VPA (500 µM) on CYP3A4 (A.) and MDR1 (B.) mRNA expression is presented as a fold increase to control non-treated cells. Data are the means ±S.D. of three individual cell samples; * p<0.05, ** p<0.01, *** p<0.001.

Fig. 6. Determination of CYP3A4 Catalytic Activity. LS174T cells were transfected with expression plasmids encoding CAR or PXR. Subsequently, cells were treated with VPA (600 µM) and specific CYP3A4-mediated testosterone 6β-hydroxylation activity was detected after 48 h. Concentration of the 6β-testosterone metabolite was determined using HPLC system in cell lysate. Final activity was normalized to sample protein concentration. Bars indicate the means ± S.D. calculated from three samples; * p<0.05.
Fig. 7. VPA synergizes with rifampicin in induction of the CYP3A4 mRNA in primary human hepatocytes. Primary human hepatocyte cultures were cultivated together with VPA and/or rifampicin (Rif) either individually or in combination, and then assayed using real time RT-PCR. CYP3A4 mRNA expression is normalized to HPRT housekeeping gene and presented as a fold increase to control non-treated cells. Values represent the means ± standard deviation (S.D.) of three independent wells. (A. and B.) 48-h exposure of primary hepatocytes to VPA (500 µM) up-regulates CYP3A4 mRNA (p <0.01). This effect of VPA was analyzed employing unpaired Student’s t-test. (C.) Rifampicin, VPA or a combination of these two drugs significantly up-regulate CYP3A4 mRNA to control (0.1% DMSO-treated cells) with p values of * p<0.05, ** p<0.01, and *** p<0.001 (unpaired Student’s t-test) after 24 h of treatment. When given in combination, the induction is in both cases statistically synergistic rather than additive, at # p<0.01 (analyzed by two-way ANOVA with interaction).

Fig. 8. The ability of CAR/RXRα heterodimer to bind CAR response elements of CYP3A4 (DR3, ER6) and MDR1 (DR4) in the presence of VPA was investigated using EMSA as described in Methods. (A.) The complex formation of CYP3A4 DR3 with CAR/RXRα was examined with in vitro translated wild-type CAR and RXRα proteins in the presence of solvent (water or DMSO 0.1% where indicated), the CAR agonist CITCO (6.25 µM; lane 5 and 7), the inverse agonist of CAR androstenol (10 µM; lane 6,7 and 9), VPA (1000 µM; lane 3, 8 and 9) or CITCO-androstenol (Andol) and VPA-androstenol combinations (lane 7 and 9). (B.) Combined gel shift/supershift experiments were performed using in vitro translated wild-type CAR protein and the nuclear fraction of HepG2 cells transfected with RXRα expression vector. The concentration-dependent effect of VPA (100, 500, 1000 µM; lane 5-7) on CAR/RXRα complex was studied. The band supershift was
performed with anti-RXRα antibody (1 μg; lane 8). (C.) Effect of VPA on CAR monomer interaction with CYP3A4 DR3. The experiments were performed using *in vitro* translated CAR without RXRα and with VPA (1000 µM) and androstenol (10 µM) as an inverse agonist of CAR. (D.) The capability of VPA (1000 µM; lane 6) to affect CAR/RXRα heterodimer interaction with MDR1 DR4 response element was tested using *in vitro* translated wild-type CAR and RXRα proteins. CITCO (6.25 µM) and androstenol (10 µM) were used as a known ligand and inverse agonist of CAR, respectively. Representative gels are shown. Band signal intensity was quantitated by densitometry and data are expressed as -fold increase (fold) relative to their vehicle controls (DMSO or water).
**Fig. 1**

<table>
<thead>
<tr>
<th></th>
<th>VPA 200 μM</th>
<th>VPA 500 μM</th>
<th>CAR</th>
<th>PXR</th>
</tr>
</thead>
<tbody>
<tr>
<td>p3A4-luc</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Luciferase activity (fold)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

- **VPA 200 μM**: No significant change.
- **VPA 500 μM**: Significant increase (++).
- **CAR**: Significant increase (++) and moderate increase (+).
- **PXR**: Significant increase (++) and moderate increase (+).
Fig. 2

 Luciferase activity (fold)

VPA 200 μM - - + + - -
VPA 500 μM - - - - + +
Rif 10 μM - + - + - -
CITCO 500 nM + - + - + -
CAR + - + - + -
PXR - + - + - +
Fig. 4

![Graph showing luciferase activity](image)

- **pPBREM-SV40-luc**
- **Luciferase activity (fold)**

<table>
<thead>
<tr>
<th>Condition</th>
<th>VPA 500 μM</th>
<th>CAR</th>
<th>PXR</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

*** indicates statistical significance.
Fig. 5

A. CYP3A4 mRNA (fold)

B. MDR1 mRNA (fold)

VPA 500 μM - + - + - +
CAR - - + + - -
PXR - - - - + +

VPA 500 μM - + - + - +
CAR - - + + - -
PXR - - - - + +
Fig. 6

CYP2A4 activity (fold)

VPA 500 μM - + - + - +
CAR - - + + - -
PXR - - - - + +

*
Fig. 7

A. Donor 1

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>VPA 500 μM</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 hour</td>
<td><img src="image" alt="CYP3A4 mRNA (fold) for 24 hour control" /></td>
<td><img src="image" alt="CYP3A4 mRNA (fold) for 24 hour VPA 500 μM" /></td>
</tr>
<tr>
<td>48 hour</td>
<td><img src="image" alt="CYP3A4 mRNA (fold) for 48 hour control" /></td>
<td><img src="image" alt="CYP3A4 mRNA (fold) for 48 hour VPA 500 μM" /></td>
</tr>
</tbody>
</table>

B. Donor 2

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>VPA 500 μM</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 hour</td>
<td><img src="image" alt="CYP3A4 mRNA (fold) for 24 hour control" /></td>
<td><img src="image" alt="CYP3A4 mRNA (fold) for 24 hour VPA 500 μM" /></td>
</tr>
<tr>
<td>48 hour</td>
<td><img src="image" alt="CYP3A4 mRNA (fold) for 48 hour control" /></td>
<td><img src="image" alt="CYP3A4 mRNA (fold) for 48 hour VPA 500 μM" /></td>
</tr>
</tbody>
</table>

C.

<table>
<thead>
<tr>
<th></th>
<th>Donor 1</th>
<th>Donor 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>VPA 500 μM</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Rif 10 μM</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

VPA 500 μM: 3.2 x **, ***, ##; Rif 10 μM: 3.2 x *, ***, ##;
**Fig. 8**

### A. CYP3A4 DR3

<table>
<thead>
<tr>
<th>lane</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>DMSO 0.1%</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CITCO 6.25 µM</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Andol 10 µM</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>VPA 1000 µM</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CAR</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**fold**

| 1.0 | 1.1 | 1.1 | 1.2 | 1.0 | 0.8 | 1.3 | 1.1 |

- CAR/RXR<sub>α</sub> complex
- Free probe

### B. CYP3A4 DR3

<table>
<thead>
<tr>
<th>lane</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>DMSO 0.1%</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CITCO 6.25 µM</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Andol 10 µM</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>VPA 100 µM</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>VPA 500 µM</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>VPA 1000 µM</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>IgG RXR&lt;sub&gt;α&lt;/sub&gt; 1 µg</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

**fold**

| 1.0 | 1.1 | 1.1 | 1.2 | 1.0 | 1.0 | 0.8 | 4.2 |

- Band shift
- CAR/RXR<sub>α</sub> - NF complex

### C. CYP3A4 DR3

<table>
<thead>
<tr>
<th>lane</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO 0.1%</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Andol 10 µM</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>VPA 1000 µM</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

**fold**

| 1.0 | 1.4 | 0.9 | 0.3 |

- CAR monomer

### D. MDR1 DR4

<table>
<thead>
<tr>
<th>lane</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO 0.1%</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CITCO 6.25 µM</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Andol 10 µM</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>VPA 1000 µM</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CAR</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**fold**

| 1.0 | 0.9 | 0.6 | 0.6 | 1.5 | 1.0 |

- CAR/RXR<sub>α</sub> complex